Skip to main content
Premium Trial:

Request an Annual Quote

New Products: NanoString Technologies' nCounter PanCancer Pathways Panel

Premium

NanoString Technologies this week launched its nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that enables translational researchers to investigate cancer biology across all major cancer pathways.

From a single tube, the PanCancer Pathways Panel simultaneously analyzes 770 genes associated with all of the key cancer pathways: PI3K, STAT, MAPK, TGFβ, Notch, Hedgehog, Wnt, apoptosis, cell cycle, RAS, chromatin modification, transcriptional regulation, and DNA damage control.

The PanCancer Pathways Panel is designed for use on NanoString's nCounter Analysis System. The assay is based on the firm's technology, which uses color-coded molecular barcodes that can hybridize directly to many different types of target molecules.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.